A subset of diffuse-type gastric cancer is susceptible to mTOR inhibitors and checkpoint inhibitors

BACKGROUND: Mechanistic target of rapamycin (mTOR) pathway is essential for the growth of gastric cancer (GC), but mTOR inhibitor everolimus was not effective for the treatment of GCs. The Cancer Genome Atlas (TCGA) researchers reported that most diffuse-type GCs were genomically stable (GS). Pathol...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:J Exp Clin Cancer Res
Main Authors: Fukamachi, Hiroshi, Kim, Seon-Kyu, Koh, Jiwon, Lee, Hye Seung, Sasaki, Yasushi, Yamashita, Kentaro, Nishikawaji, Taketo, Shimada, Shu, Akiyama, Yoshimitsu, Byeon, Sun-ju, Bae, Dong-Hyuck, Okuno, Keisuke, Nakagawa, Masatoshi, Tanioka, Toshiro, Inokuchi, Mikito, Kawachi, Hiroshi, Tsuchiya, Kiichiro, Kojima, Kazuyuki, Tokino, Takashi, Eishi, Yoshinobu, Kim, Yong Sung, Kim, Woo Ho, Yuasa, Yasuhito, Tanaka, Shinji
פורמט: Artigo
שפה:Inglês
יצא לאור: BioMed Central 2019
נושאים:
Research
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC6416873/
https://ncbi.nlm.nih.gov/pubmed/30866995
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13046-019-1121-3
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים